Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Gross Profit (2021 - 2025)

Tg Therapeutics (TGTX) has 5 years of Gross Profit data on record, last reported at $154.4 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 66.44% year-over-year to $154.4 million; the TTM value through Dec 2025 reached $515.6 million, up 77.47%, while the annual FY2025 figure was $515.6 million, 77.47% up from the prior year.
  • Gross Profit reached $154.4 million in Q4 2025 per TGTX's latest filing, up from $133.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $162.3 million in Q3 2023 and bottomed at $77000.0 in Q4 2022.
  • Average Gross Profit over 5 years is $73.3 million, with a median of $69.8 million recorded in 2024.
  • Peak YoY movement for Gross Profit: skyrocketed 46803.9% in 2023, then plummeted 54.08% in 2024.
  • A 5-year view of Gross Profit shows it stood at $654000.0 in 2021, then tumbled by 88.23% to $77000.0 in 2022, then surged by 46803.9% to $36.1 million in 2023, then surged by 156.91% to $92.8 million in 2024, then surged by 66.44% to $154.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $154.4 million in Q4 2025, $133.6 million in Q3 2025, and $122.2 million in Q2 2025.